atai Life Sciences to Participate in Upcoming March Investor Conferences
March 21 2022 - 1:07PM
atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage
biopharmaceutical company aiming to transform the treatment of
mental health disorders, will participate in the following upcoming
investor conferences in March:
- Citi Winter Biotech Virtual Bus TourFormat:
Fireside Chat - VirtualDate and Time: Tuesday, March 22nd, 11:00
a.m. ET – 11:40 a.m. ETConference Link: URL
- Maxim Group 2022 Virtual Growth
ConferenceFormat: Company Presentation - VirtualDate and
Time: Monday, March 28th, 2022 – Wednesday, March 30th,
2022Conference Link: URL
The presentations and archived webcasts will also be accessible
in the Events section of atai’s website.
About atai Life Sciences atai is a
clinical-stage biopharmaceutical company aiming to transform the
treatment of mental health disorders. atai was founded in 2018 as a
response to the significant unmet need and lack of innovation in
the mental health treatment landscape. atai is dedicated to
acquiring, incubating and efficiently developing innovative
therapeutics to treat depression, anxiety, addiction, and other
mental health disorders.
atai's business model combines funding, technology, scientific
and regulatory expertise with a focus on psychedelic therapy and
other drugs with differentiated safety profiles and therapeutic
potential. By pooling resources and best practices, atai aims to
responsibly accelerate the development of new medicines across its
companies, seeking to effectively treat and ultimately heal mental
health disorders.
atai's vision is to heal mental health disorders so that
everyone, everywhere can live a more fulfilled life. atai has
offices in New York, London, and Berlin. For more information,
please visit www.atai.life.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to
be forward-looking statements. Forward-looking statements are
neither promises nor guarantees, but involve known and unknown
risks and uncertainties that could cause actual results to differ
materially from those projected, including, without limitation, the
important factors discussed under the caption “Risk Factors” in
atai's prospectus pursuant to Rule 424(b) filed with the U.S.
Securities and Exchange Commission (“SEC”) on June 21, 2021, as
such factors may be updated from time to time in atai's other
filings with the SEC. atai disclaims any obligation or undertaking
to update or revise any forward-looking statements contained in
this press release, other than to the extent required by applicable
law.
Contact Information
Investor Contact:Greg WeaverChief Financial Officer, atai Life
SciencesEmail: greg.weaver@atai.life
Media Contact:Camilla DormerVP, Communications, atai Life
SciencesEmail: camilla@atai.life
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
ATAI Life Sciences NV (NASDAQ:ATAI)
Historical Stock Chart
From Sep 2023 to Sep 2024